1. Home
  2. AGPU vs MBRX Comparison

AGPU vs MBRX Comparison

Compare AGPU & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$3.94

Market Cap

6.9M

Sector

N/A

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.61

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGPU
MBRX
Founded
2002
2015
Country
United States
United States
Employees
24
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
AGPU
MBRX
Price
$3.94
$2.61
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
4.9M
86.4K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12,476.23
N/A
Revenue Next Year
$55.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.25
52 Week High
$9.00
$7.98

Technical Indicators

Market Signals
Indicator
AGPU
MBRX
Relative Strength Index (RSI) 63.70 56.73
Support Level $1.14 $0.39
Resistance Level $8.72 $5.15
Average True Range (ATR) 0.90 0.14
MACD 0.33 0.09
Stochastic Oscillator 54.88 96.07

Price Performance

Historical Comparison
AGPU
MBRX

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Share on Social Networks: